{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:42:59Z","timestamp":1782258179246,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302026"],"award-info":[{"award-number":["82302026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical research has suggested that chronic HBV infection exerts a certain effect on the occurrence of cardiovascular disease by regulating cholesterol metabolism in liver cells. High serum apolipoprotein B\/apolipoprotein A1 (ApoB\/ApoA1) ratio plays a certain role in the above regulation, and it serves as a risk factor for cardiovascular disease. However, whether the ApoB\/ApoA1 ratio is correlated with chronic HBV infection and its disease progression remains unclear. In accordance with the inclusion and exclusion criteria, all 378 participants administrated at Renmin Hospital of Wuhan University from March 2021 to March 2022, fell into Healthy Control (HC) group (50 participants), Hepatocellular carcinoma (HCC) group (107 patients), liver cirrhosis (LC) group (64 patients), chronic hepatitis B (CHB) group (62 patients), chronic hepatitis C (CHC) group (46 patients) and Hepatitis E Virus (HEV) group (49 patients). Serum ApoA1 and ApoB concentrations were measured at admission, and the ApoB\/ApoA1 ratio was determined. The levels of laboratory parameters in the respective group were compared and ApoB\/ApoA1 ratios in HCC patients and LC patients with different severity were further analyzed. ROC curves were plotted to analyze the early diagnostic ability of ApoB\/ApoA1 ratio for HBV-associated HCC. Logistic regression and restricted cubic spline analysis were used to explore the correlation between ApoB\/ApoA1 ratio and LC and HCC risk. A comparison was drawn in terms of ApoB\/ApoA1 ratio between the groups, and the result was expressed in descending sequence: HEV group\u2009&gt;\u2009CHB group\u2009&gt;\u2009LC group\u2009&gt;\u2009HCC group\u2009&gt;\u2009CHC group\u2009&gt;\u2009HC group, early-stage HCC\u2009&lt;\u2009middle-stage HCC\u2009&lt;\u2009advanced-stage HCC, Class A LC\u2009&lt;\u2009Class B LC\u2009&lt;\u2009Class C LC. Serum ApoB\/ApoA1 ratio combined diagnosis with AFP exhibited the capability of increasing the detection efficacy and specificity of AFP for HCC and AFP-negative HCC. The incidence of LC and HCC in the respective logistic regression model showed a negative correlation with the serum ApoB\/ApoA1 ratio in CHB patients (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). After all confounding factors covered in this study were regulated, the result of the restricted cubic spline analysis suggested that in a certain range, serum ApoB\/ApoA1 ratio showed an inverse correlation with the prevalence of LC or HCC in CHB patients. Serum ApoB\/ApoA1 ratio in CHB patients may be conducive to identifying high-risk patients for HCC or LC, such that LC and HCC can be early diagnosed and treated.<\/jats:p>","DOI":"10.1038\/s41598-024-61820-x","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T09:02:17Z","timestamp":1715677337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Serum ApoB\/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Xin","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"12","key":"61820_CR1","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3748\/wjg.v28.i12.1226","volume":"28","author":"N Marascio","year":"2022","unstructured":"Marascio, N. et al. Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice. World J. Gastroenterol. 28(12), 1226\u20131238. https:\/\/doi.org\/10.3748\/wjg.v28.i12.1226 (2022).","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"61820_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nri3623","volume":"14","author":"A Pellicoro","year":"2014","unstructured":"Pellicoro, A., Ramachandran, P., Iredale, J. P. & Fallowfield, J. A. Liver fibrosis and repair: Immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14(3), 181\u2013194. https:\/\/doi.org\/10.1038\/nri3623 (2014).","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"61820_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 71(3), 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"61820_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn, K. A., Petrick, J. L. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma. Hepatology (Baltimore, Md.) 73(1), 4\u201313. https:\/\/doi.org\/10.1002\/hep.31288 (2021).","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"5","key":"61820_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik, J. M., Golabi, P., Younossi, Y., Mishra, A. & Younossi, Z. M. Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD. Hepatology (Baltimore, Md.) 72(5), 1605\u20131616. https:\/\/doi.org\/10.1002\/hep.31173 (2020).","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"17","key":"61820_CR6","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"LSY Tang","year":"2018","unstructured":"Tang, L. S. Y., Covert, E., Wilson, E. & Kottilil, S. Chronic hepatitis B infection: A review. JAMA 319(17), 1802\u20131813. https:\/\/doi.org\/10.1001\/jama.2018.3795 (2018).","journal-title":"JAMA"},{"key":"61820_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.965548","volume":"13","author":"E Tourkochristou","year":"2022","unstructured":"Tourkochristou, E., Assimakopoulos, S. F., Thomopoulos, K., Marangos, M. & Triantos, C. NAFLD and HBV interplay - related mechanisms underlying liver disease progression. Front. Immunol. 13, 965548. https:\/\/doi.org\/10.3389\/fimmu.2022.965548 (2022).","journal-title":"Front. Immunol."},{"issue":"11","key":"61820_CR8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2(11), 901\u2013910. https:\/\/doi.org\/10.1016\/S2213-8587(14)70032-4 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"26","key":"61820_CR9","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.3748\/wjg.v27.i26.3971","volume":"27","author":"YW Shi","year":"2021","unstructured":"Shi, Y. W., Yang, R. X. & Fan, J. G. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. World J. Gastroenterol. 27(26), 3971\u20133983. https:\/\/doi.org\/10.3748\/wjg.v27.i26.3971 (2021).","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"61820_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu, Y. C., Huang, D. Q. & Nguyen, M. H. Global burden of hepatitis B virus: Current status, missed opportunities and a call for action. Nat. Rev. Gastroenterol. Hepatol. 20(8), 524\u2013537. https:\/\/doi.org\/10.1038\/s41575-023-00760-9 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"61820_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2337\/dc18-0040","volume":"41","author":"M Khalili","year":"2018","unstructured":"Khalili, M. et al. Relationship between metabolic syndrome, alanine aminotransferase levels, and liver disease severity in a multiethnic North American cohort with chronic hepatitis B. Diabetes Care 41(6), 1251\u20131259. https:\/\/doi.org\/10.2337\/dc18-0040 (2018).","journal-title":"Diabetes Care"},{"issue":"2","key":"61820_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3350\/cmh.2022.0422","volume":"29","author":"SC Huang","year":"2023","unstructured":"Huang, S. C. & Liu, C. J. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives. Clin. Mol. Hepatol. 29(2), 320\u2013331. https:\/\/doi.org\/10.3350\/cmh.2022.0422 (2023).","journal-title":"Clin. Mol. Hepatol."},{"issue":"3","key":"61820_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jhep.2021.09.024","volume":"76","author":"TC Yip","year":"2022","unstructured":"Yip, T. C., Lee, H. W., Chan, W. K., Wong, G. L. & Wong, V. W. Asian perspective on NAFLD-associated HCC. J. Hepatol. 76(3), 726\u2013734. https:\/\/doi.org\/10.1016\/j.jhep.2021.09.024 (2022).","journal-title":"J. Hepatol."},{"issue":"3","key":"61820_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jprot.2011.09.011","volume":"75","author":"N Xie","year":"2012","unstructured":"Xie, N. et al. Comprehensive proteomic analysis of host cell lipid rafts modified by HBV infection. J. Proteom. 75(3), 725\u2013739 (2012).","journal-title":"J. Proteom."},{"key":"61820_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jprot.2013.03.028","volume":"84","author":"T Zhang","year":"2013","unstructured":"Zhang, T. et al. An integrated proteomics and bioinformatics analyses of hepatitis B virus X interacting proteins and identification of a novel interactor apoA-I. J. Proteom. 84, 92\u2013105 (2013).","journal-title":"J. Proteom."},{"key":"61820_CR16","doi-asserted-by":"publisher","first-page":"1026243","DOI":"10.3389\/fcvm.2022.1026243","volume":"9","author":"Y Wang","year":"2022","unstructured":"Wang, Y. & He, J. Correlation of cardiovascular risk predictors with overweight and obesity in patients with familial hypercholesterolemia. Front. Cardiovasc. Med. 9, 1026243. https:\/\/doi.org\/10.3389\/fcvm.2022.1026243 (2022).","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"61820_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.gendis.2021.12.007","volume":"10","author":"C Xu","year":"2022","unstructured":"Xu, C., Li, H. & Tang, C. K. Sterol carrier protein 2: A promising target in the pathogenesis of atherosclerosis. Genes Dis. 10(2), 457\u2013467. https:\/\/doi.org\/10.1016\/j.gendis.2021.12.007 (2022).","journal-title":"Genes Dis."},{"issue":"1","key":"61820_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40121-022-00725-6","volume":"12","author":"Y Diao","year":"2023","unstructured":"Diao, Y. et al. Metabolic syndrome, nonalcoholic fatty liver disease, and chronic hepatitis B: A narrative review. Infect. Dis. Therapy 12(1), 53\u201366. https:\/\/doi.org\/10.1007\/s40121-022-00725-6 (2023).","journal-title":"Infect. Dis. Therapy"},{"issue":"30","key":"61820_CR19","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.3748\/wjg.v27.i30.5112","volume":"27","author":"M Riveiro-Barciela","year":"2021","unstructured":"Riveiro-Barciela, M. et al. Na\u00efve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. World J. Gastroenterol. 27(30), 5112\u20135125. https:\/\/doi.org\/10.3748\/wjg.v27.i30.5112 (2021).","journal-title":"World J. Gastroenterol."},{"key":"61820_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.636897","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: A potential target of antiviral therapy for chronic hepatitis B. Front. Microbial. 12, 636897. https:\/\/doi.org\/10.3389\/fmicb.2021.636897 (2021).","journal-title":"Front. Microbial."},{"key":"61820_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1476-511X-13-130","volume":"13","author":"W Jiang","year":"2014","unstructured":"Jiang, W., Zheng, L., Yang, Q., Huang, Z. & Wang, X. Investigation into the effect of hepatitis B virus on apoliprotein A1 expression and its mechanism. Lipids Health Dis. 13, 130. https:\/\/doi.org\/10.1186\/1476-511X-13-130 (2014).","journal-title":"Lipids Health Dis."},{"issue":"5","key":"61820_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3390\/v13050745","volume":"13","author":"A Vaillant","year":"2021","unstructured":"Vaillant, A. Transaminase elevations during treatment of chronic hepatitis B infection: Safety considerations and role in achieving functional cure. Viruses 13(5), 745. https:\/\/doi.org\/10.3390\/v13050745 (2021).","journal-title":"Viruses"},{"issue":"12","key":"61820_CR23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.007","volume":"27","author":"Chinese Society of Infectious Diseases, Chinese Medical Association, & Chinese Society of Hepatology, Chinese Medical Association","year":"2019","unstructured":"Chinese Society of Infectious Diseases, Chinese Medical Association, & Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Chin. J. Hepatol. 27(12), 938\u2013961. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2019.12.007 (2019).","journal-title":"Chin. J. Hepatol."},{"issue":"11","key":"61820_CR24","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3760\/cma.j.issn.1007-3418.2019.11.008","volume":"27","author":"Chinese Society of Hepatology, Chinese Medical Association","year":"2019","unstructured":"Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi 27(11), 846\u2013865. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2019.11.008 (2019).","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"61820_CR25","doi-asserted-by":"publisher","unstructured":"Chinese Society of Hepatology and Chinese Society of Infectious Diseases, & Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C (2022 version). Zhong hua Gan Zang Bing Za Zhi. 30 (12), 1332\u20131348. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20221220-00605 (2022).","DOI":"10.3760\/cma.j.cn501113-20221220-00605"},{"issue":"7","key":"61820_CR26","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3760\/cma.j.cn112152-20220418-00265","volume":"44","author":"National Cancer Center, & Liver Cancer Expert Committee of National Cancer Quality Control Center","year":"2022","unstructured":"National Cancer Center, & Liver Cancer Expert Committee of National Cancer Quality Control Center. Quality control index for standardized diagnosis and treatment of primary liver cancer in China (2022 edition). Zhonghua Zhong Liu Za Zhi. 44(7), 600\u2013608. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20220418-00265 (2022).","journal-title":"Zhonghua Zhong Liu Za Zhi."},{"key":"61820_CR27","first-page":"1577","volume":"12","author":"ZP Miao","year":"2016","unstructured":"Miao, Z. P. & Chen, E. F. Deliberation on the diagnostic criteria for hepatitis E. Chin. Rural Health Serv. Adm. 12, 1577\u20131580 (2016).","journal-title":"Chin. Rural Health Serv. Adm."},{"key":"61820_CR28","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"MF Yuen","year":"2018","unstructured":"Yuen, M. F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Prim. 4, 18035. https:\/\/doi.org\/10.1038\/nrdp.2018.35 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"11","key":"61820_CR29","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1136\/gut.2005.065136","volume":"54","author":"MF Yuen","year":"2005","unstructured":"Yuen, M. F. et al. Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications. Gut 54(11), 1610\u20131614. https:\/\/doi.org\/10.1136\/gut.2005.065136 (2005).","journal-title":"Gut"},{"issue":"4","key":"61820_CR30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/v15040997","volume":"15","author":"YS Lim","year":"2023","unstructured":"Lim, Y. S. et al. Evidence for benefits of early treatment initiation for chronic hepatitis B. Viruses 15(4), 997. https:\/\/doi.org\/10.3390\/v15040997 (2023).","journal-title":"Viruses"},{"key":"61820_CR31","doi-asserted-by":"publisher","first-page":"1062172","DOI":"10.3389\/fcimb.2023.1062172","volume":"13","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. A novel prognostic model for predicting the risk of first variceal hemorrhage in patients with HBV-related cirrhosis. Front. Cell. Infect. Microbial. 13, 1062172. https:\/\/doi.org\/10.3389\/fcimb.2023.1062172 (2023).","journal-title":"Front. Cell. Infect. Microbial."},{"issue":"1","key":"61820_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","volume":"50","author":"MF Yuen","year":"2009","unstructured":"Yuen, M. F. et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J. Hepatol. 50(1), 80\u201388. https:\/\/doi.org\/10.1016\/j.jhep.2008.07.023 (2009).","journal-title":"J. Hepatol."},{"key":"61820_CR33","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3389\/fonc.2020.01316","volume":"10","author":"T Wang","year":"2020","unstructured":"Wang, T. & Zhang, K. H. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front. Oncol. 10, 1316 (2020).","journal-title":"Front. Oncol."},{"issue":"6","key":"61820_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","volume":"12","author":"HI Yang","year":"2011","unstructured":"Yang, H. I. et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score. Lancet Oncol. 12(6), 568\u2013574. https:\/\/doi.org\/10.1016\/S1470-2045(11)70077-8 (2011).","journal-title":"Lancet Oncol."},{"issue":"4","key":"61820_CR35","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","volume":"64","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis, G. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J. Hepatol. 64(4), 800\u2013806. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.035 (2016).","journal-title":"J. Hepatol."},{"issue":"2","key":"61820_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/apt.15575","volume":"51","author":"CC Wang","year":"2020","unstructured":"Wang, C. C., Cheng, P. N. & Kao, J. H. Systematic review: Chronic viral hepatitis and metabolic derangement. Aliment. Pharmacol. Ther. 51(2), 216\u2013230. https:\/\/doi.org\/10.1111\/apt.15575 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"61820_CR37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/JHC.S283840","volume":"9","author":"NC Chavez-Tapia","year":"2022","unstructured":"Chavez-Tapia, N. C. et al. Understanding the role of metabolic syndrome as a risk factor for hepatocellular carcinoma. J. Hepatocellular Carcinoma 9, 583\u2013593. https:\/\/doi.org\/10.2147\/JHC.S283840 (2022).","journal-title":"J. Hepatocellular Carcinoma"},{"issue":"1","key":"61820_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12944-019-1084-6","volume":"18","author":"Y Cui","year":"2019","unstructured":"Cui, Y., Cui, X. D., Xu, M., Fang, M. & Cai, M. J. Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients. Lip. Health Dis. 18(1), 138. https:\/\/doi.org\/10.1186\/s12944-019-1084-6 (2019).","journal-title":"Lip. Health Dis."},{"issue":"1","key":"61820_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/pathogens12010029","volume":"12","author":"AJ Walter","year":"2022","unstructured":"Walter, A. J., van de Klundert, M. A. & Jung, S. Many ways to communicate-crosstalk between the HBV-infected cell and its environment. Pathogens (Basel, Switzerland). 12(1), 29. https:\/\/doi.org\/10.3390\/pathogens12010029 (2022).","journal-title":"Pathogens (Basel, Switzerland)."},{"issue":"23","key":"61820_CR40","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.3390\/cancers14235742","volume":"14","author":"A Gaballah","year":"2022","unstructured":"Gaballah, A. & Bartosch, B. An update on the metabolic landscape of oncogenic viruses. Cancers 14(23), 5742. https:\/\/doi.org\/10.3390\/cancers14235742 (2022).","journal-title":"Cancers"},{"issue":"9","key":"61820_CR41","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41423-023-01026-9","volume":"20","author":"Z Xun","year":"2023","unstructured":"Xun, Z., Yao, X. & Ou, Q. Emerging roles of bile acids in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cell. Mol. Immunol. 20(9), 1087\u20131089. https:\/\/doi.org\/10.1038\/s41423-023-01026-9 (2023).","journal-title":"Cell. Mol. Immunol."},{"key":"61820_CR42","doi-asserted-by":"publisher","first-page":"1033314","DOI":"10.3389\/fimmu.2022.1033314","volume":"13","author":"O Diaz","year":"2022","unstructured":"Diaz, O., Vidalain, P. O., Rami\u00e8re, C., Lotteau, V. & Perrin-Cocon, L. What role for cellular metabolism in the control of hepatitis viruses?. Front. Immunol. 13, 1033314. https:\/\/doi.org\/10.3389\/fimmu.2022.1033314 (2022).","journal-title":"Front. Immunol."},{"issue":"2","key":"61820_CR43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/v15020512","volume":"15","author":"H Yan","year":"2023","unstructured":"Yan, H. & Wang, C. Key factors for \u201cFishing\u201d NTCP as a functional receptor for HBV and HDV. Viruses 15(2), 512. https:\/\/doi.org\/10.3390\/v15020512 (2023).","journal-title":"Viruses"},{"issue":"5","key":"61820_CR44","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1002\/hep.27224","volume":"60","author":"A Geier","year":"2014","unstructured":"Geier, A. Hepatitis B virus: The \u201cmetabolovirus\u201d highjacks cholesterol and bile acid metabolism. Hepatology (Baltimore, Md.). 60(5), 1458\u20131460. https:\/\/doi.org\/10.1002\/hep.27224 (2014).","journal-title":"Hepatology (Baltimore, Md.)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61820-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T09:06:51Z","timestamp":1715677611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61820-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["61820"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-61820-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"25 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10996"}}